drugset / Trial / NCT06455293

Psilocybin Therapy for Depression in Parkinson's Disease

NCT06455293

Phase 2 Recruiting 60 enrolled Joshua Woolley, MD, PhD
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Timeline

Start
2024-08-19
Primary completion
2027-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimavanserin Small molecule
Subject Psilocybin Other / unclassified Oral